MetLife Investment Management LLC Sells 454 Shares of Repligen Co. (NASDAQ:RGEN)

MetLife Investment Management LLC lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 1.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 27,346 shares of the biotechnology company’s stock after selling 454 shares during the period. MetLife Investment Management LLC’s holdings in Repligen were worth $4,070,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of RGEN. Andra AP fonden acquired a new position in shares of Repligen in the second quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new position in Repligen in the 2nd quarter worth $33,000. UMB Bank n.a. boosted its stake in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC increased its holdings in Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RGEN shares. Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company assumed coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Stock Performance

Shares of RGEN opened at $150.46 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a 50-day moving average of $141.18 and a 200-day moving average of $142.27. The company has a market cap of $8.43 billion, a PE ratio of -406.64, a price-to-earnings-growth ratio of 4.53 and a beta of 0.96. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the business earned $0.23 earnings per share. The business’s revenue was up 9.7% compared to the same quarter last year. As a group, equities analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.